Stock VYNE VYNE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
2.63 USD +5.20% Intraday chart for VYNE Therapeutics Inc. +11.91% +12.88%
Apr. 04 Transcript : VYNE Therapeutics Inc. - Special Call
Feb. 29 VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
AQ
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
AQ
VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium
AQ
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
AQ
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
AQ
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors
AQ
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
AQ
VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023
AQ
VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million
AQ
VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202
AQ
VYNE Therapeutics Announces Private Placement of $88 Million
AQ
VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo
AQ
VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
AQ
VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
AQ
VYNE Therapeutics to Attend BIO International Convention
AQ
VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
AQ
University of Dundee : Spinout agrees potential $50 million deal
AQ
VYNE THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions
AQ
VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VYNE Stock
  4. News VYNE Therapeutics Inc.
  5. Press Releases